Jefferies Financial Group Inc. Purchases 14,711 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Jefferies Financial Group Inc. raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 123.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,606 shares of the company's stock after buying an additional 14,711 shares during the quarter. Jefferies Financial Group Inc.'s holdings in IDEXX Laboratories were worth $11,000,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sax Wealth Advisors LLC lifted its position in IDEXX Laboratories by 76.3% during the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock worth $590,000 after acquiring an additional 617 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock valued at $3,199,000 after acquiring an additional 800 shares during the last quarter. Paragon Capital Management Inc. grew its stake in IDEXX Laboratories by 25.7% during the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock worth $1,579,000 after buying an additional 782 shares during the last quarter. Manitou Investment Management Ltd. grew its stake in IDEXX Laboratories by 491.0% during the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock worth $21,582,000 after buying an additional 43,369 shares during the last quarter. Finally, Fiera Capital Corp grew its stake in IDEXX Laboratories by 12.3% during the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock worth $58,377,000 after buying an additional 15,463 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on IDXX shares. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Morgan Stanley upped their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Finally, Stifel Nicolaus reduced their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research report on Monday, April 14th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $524.75.

IDEXX Laboratories Stock Up 1.2%

Shares of IDXX stock traded up $6.11 on Friday, hitting $518.10. 524,927 shares of the stock were exchanged, compared to its average volume of 649,734. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $41.67 billion, a P/E ratio of 48.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The business has a 50-day moving average of $431.28 and a 200 day moving average of $431.28. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $545.43.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the prior year, the firm posted $2.71 earnings per share. The business's quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.